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Background: Shikimic acid (SA) is a key chiral starting molecule for the synthesis of the neuramidase inhibitor
GS4104 against viral influenza. Microbial production of SA has been extensively investigated in Escherichia coli, and
to a less extent in Bacillus subtilis. However, metabolic flux of the high SA-producing strains has not been explored.
In this study, we constructed with genetic manipulation and further determined metabolic flux with 13C-labeling
test of high SA-producing B. subtilis strains.
Results: B. subtilis 1A474 had a mutation in SA kinase gene (aroI) and accumulated 1.5 g/L of SA. Overexpression of
plasmid-encoded aroA, aroB, aroC or aroD in B. subtilis revealed that aroD had the most significantly positive effects
on SA production. Simultaneous overexpression of genes for 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase
(aroA) and SA dehydrogenase (aroD) in B. subtilis BSSA/pSAAroA/pDGSAAroD resulted in SA production of 3.2 g/L.
13C-Metabolic flux assay (MFA) on the two strains BSSA/pHCMC04/pDG148-stu and BSSA/pSAAroA/pDGSAAroD
indicated the carbon flux from glucose to SA increased to 4.6% in BSSA/pSAAroA/pDGSAAroD from 1.9% in strain
BSSA/pHCMC04/pDG148-stu. The carbon flux through tricarboxylic acid cycle significantly reduced, while responses of
the pentose phosphate pathway and the glycolysis to high SA production were rather weak, in the strain
BSSA/pSAAroA/pDGSAAroD. Based on the results from MFA, two potential targets for further optimization of SA
production were identified. Experiments on genetic deletion of phosphoenoylpyruvate kinase gene confirmed its
positive influence on SA production, while the overexpression of the transketolase gene did not lead to increase in
SA production.
Conclusion: Of the genes involved in shikimate pathway in B. subtilis, aroD exerted most significant influence
on SA accumulation. Overexpression of plasmid-encoded aroA and aroD doubled SA production than its parent
strain. MFA revealed metabolic flux redistribution among phosphate pentose pathway, glycolysis, TCA cycle in the
low and high SA-producing B. subtilis strains. The high SA producing strain BSSA/pSAAroA/pDGSAAroD had
increased carbon flux into shikimate pathway and reduced flux into TCA cycle.
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Shikimic acid (3,4,5-trihydroxy-1-cyclohexene-1-carboxylic
acid, SA), is a key chiral starting material for the synthesis
of the antiviral neuraminidase inhibitor GS4104 [1,2]. It is
a key metabolic intermediate of the shikimate pathway for
biosynthesis of aromatic amino acids (L-Phe, L-Trp, and
L-Tyr) and many alkaloids in plants and microorganisms
[3-5]. As a commercial product, SA has been extracted
from the fruits of the Illicium plant. However, microbial
fermentation as an alternative process for SA production
has attracted more and more interests.
Beginning with phosphoenolpyruvate (PEP) and ery-
throse-4-phosphate (E4P), SA is synthesized via first 4
reactions of the shikimate pathway (Figure 1). This
shikimate pathway is essential to bacterial growth and
there has been no report on excessive accumulation of SA
by microorganisms. Genetic manipulation and metabolic
engineering approaches had been applied to modifyFigure 1 Pathway of shikimic acid biosynthesis and its regulation
in B. subtilis. Abbreviations used: CHA, chorismate; DAHP, 3-deoxy-d-
arobino-heptulosonate 7-phosphate; DHQ, 3-dehydroquinate; DHS,
3-dehydroshikimate; EPSP, 5-enolpyruvoylshikimate 3-phosphate; E4P,
erythrose 4-phosphate; L-Phe, L-phenylalanine; L-Trp, L-tryptophan;
L-Tyr, L-tyrosine; PEP, phosphoenolpyruvate; SA, shikimate; S3P,
shikimate 3-phosphate.several microorganisms, particular Escherichia coli, for
SA accumulation [6-9]. One strategy was to increase the
supply of PEP and/or E4P, thus more carbon substrate
channeled into SA synthesis. For examples, the PEP-
consuming glucose transfer system (PTS) was replaced
by non-PEP-consuming glucose facilitators, and trans-
ketolase I (tktA) and PEP synthase (ppsA) genes were
overexpressed to increase the availability of E4P and
PEP [10-14]. A second strategy was to block SA flux into
chorismic acid by inactivating SA kinases (aroK and aroL)
genes, and resulting the accumulation of SA in large
quantity [6,15]. A third strategy was overexpression of
feedback-resistant (fbr) 3-deoxy-D-arabinoheptulosonate-
7-phosphate (DAHP) synthase genes (e.g. aroFfbr and
aroGfbr), thus avoided feedback inhibition in the first
step of the shikimate pathway [7,16]. It was reported
that high amount of extracellular shikimic acids activated
the shikimic acid transporter ShiA (shiA) and invoked
transport of SA back into cells. So, a forth strategy was to
inactivate the shiA thus vanished the uptake of SA back
into cell and diminished intracellular accumulation of
3-dehydroshikimic acid as well [9]. Besides E. coli, efforts
were also made to convert Bacillus subtilis into a SA
accumulator. According to a patent description [17], gen-
etic deletion of SA kinase gene (aroI) and overexpression
of bacilli DAHP synthase (aroA) and SA dehydrogenase
(aroD) genes resulted in a significant accumulation of SA
in B. subtilis. So far as we know, intensive evaluation of
aro genes on SA production has not been reported in
B. subtilis. Furthermore, knowledge of the metabolic fluxes
of those genetically engineered strains of E. coli and B.
subtilis is still missing.
In this study, we investigated the metabolic fluxes
with 13C-labeled glucose in two genetically modified,
SA-producing strains of B. subtilis, namely BSSA/pHCM
C04/pDG148-stu and BSSA/pSAAroA/pDGSAAroD. Our
results indicated that significant metabolic flux changes
occurred for the shikimate pathway, tricarboxylic acid
(TCA) cycle, and reactions involving PEP and E4P
generation and consumption. Based on the 13C-label-
ing metabolic flux assay (MFA), we further created
mutants for SA production. The highest SA-producing
B. subtilis strain produced 3.46 g/L of SA during batch
cultivation in flasks.
Results
Strain construction and SA productivity
B. subtilis strain 1A474 had been used for genome mapping
and its genome had a mutation on the SA kinase gene
(aroI). In this study, we identified that this specific mutation
of aroI was resulted from a single mutation of C to G,
leading to Arg129 (coded by CGC) being replaced by
Cys129 (UGC). Phenotypically, strain 1A474 was not able
to grow on minimal medium and it restored growth
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determined that strain 1A474 accumulated up to 1.5 g/L
of SA in batch cultivation (Table 1).
Strain 1A474 was used to construct high SA producers.
For this purpose, we adopted a strategy to overexpress
aro genes involving shikimate pathway in strain 1A474.
The gene aroA, aroB, aroC, and aroD were cloned from
the genome of strain 168 and were individually overex-
pressed in strain 1A474. SA production by the resulting
recombinant strains was determined and was compared to
their parent strains. Results showed that overexpression
of plasmid-encoded aroA (strain BSSA/pSAAroA), aroB
(strain BSSA/pSAAroB), or aroC (strain BSSA/pSAAroC),
exhibited no significant increase in SA production,
however, the overexpression of plasmid-encoded aroD
in strain BSSA/pSAAroD resulted in higher production
of SA (2.3 g/L, an increase of 53%), compared to its
parent strain (1.5 g/L) (Table 1).
In order to improve SA production further, we co-
overexpressed aroA, aroB, or aroC with aroD in B. subtilis.
Results showed that co-overexpression of aroA (strain
BSSA/pSAAroA/pDGSAAroD), aroB (strain BSSA/pSAAro
B/pDGSAAroD), or aroC (strain BSSA/pSAAroC/pDG
SAAroD) with aroD indeed increased SA production
compared to strain BSSA/pHCMC04/ pDGSAAroD and
parent strain 1A474 (Table 1). We also found that double
overexpression of aroD on two plasmids further increased
SA production compared to single overexpression of aroD
(Table 1). Strain BSSA/pSAAroA/pDGSAAroD that co-
overexpressed aroA and aroD was the best SA producer,
with SA production of 3.2 g/L during batch cultivation
fermentation. Compared to the parent strain 1A474, SA
production was doubled in strain BSSA/pSAAroA/
pDGSAAroD (Table 1).Table 1 Production of shikimic acid by various recombinant s
Strains Shikimic acid*(g/L) Cha
1A474 1.50 ± 0.22
BSSA/pHCMC04 1.81 ± 0.18
BSSA/pSAAroA 1.42 ± 0.20
BSSA/pSAAroB 1.74 ± 0.23
BSSA/pSAAroC 1.77 ± 0.15
BSSA/pSAAroD 2.30 ± 0.17
BSSA/pSAAroA/ pDGSAAroD 3.20 ± 0.07
BSSA/pSAAroB/pDGSAAroD 2.99 ± 0.05
BSSA/pSAAroC/pDGSAAroD 2.90 ± 0.03
BSSA/pSAAroD pDGSAAroD 2.91 ± 0.04
BSSA(Ωtkt::pSATkt) 3.11 ± 0.03
BSSA(Ωpyk::pSAPyk) 3.46 ± 0.04
*The shikimic acid concentrations in the culture supernatants were averages of the
shikimic acid production.
#For detailed genotypes, see Table 3.Phenotypic characterization of growth, glucose
consumption and metabolite production with strains
BSSA474a and BSSA47407
Figure 2 showed cell growth (OD600), glucose consumption,
SA production, and 3-dehydroshikimic acid production
of strains BSSA/pHCMC04/pDG148-stu and BSSA/pSA
AroA/pDGSAAroD in M9 minimal medium supplemented
with 5 g/L glucose. Strain BSSA/pHCMC04/pDG148-
stu grew slightly faster than BSSA/pSAAroA/pDGSAAroD
did, but they reached almost identical cell mass (OD600)
at the end of cultivation. The consumption of glucose
was faster by BSSA/pHCMC04/pDG148-stu than BSSA/
pSAAroA/pDGSAAroD. The concentrations of two me-
tabolites, namely SA and 3-dehydroshikimic acid, were
determined. Strain BSSA/pHCMC04/pDG148-stu pro-
duced equal amounts of SA and 3-dehydroshikimic acid
(Table 2, 1.1 mM), at a molar ratio of 1:1. Strain BSSA/
pSAAroA/pDGSAAroD accumulated more SA (1.49 mM)
than 3-dehydroshikimic acid (0.35 mM), at a molar ratio
of 4.3:1. For the purpose of metabolic flux analysis, we
calculated the specific cell growth (μ), specific glucose
consumption (qglu), specific shikimic acid production
(qsa), and specific 3-dehydroshikimic acid production
(qdhs) rates, and they are listed in Table 2.Metabolic flux responses to high production of SA in
strain BSSA47407
Metabolic flux analysis by GC/LC-MS
The 13C-based metabolic flux analysis was performed
for the strains BSSA/pHCMC04/pDG148-stu and BSSA/
pSAAroA/pDGSAAroD grown in the medium containing
either 100% [1-13C] glucose or 20% [U-13C] glucose and
80% unlabeled glucose. The mass isotopomer patterns intrains of Bacillus subtilis
nges (%) Notes#
100.0 Parent strain
120.7 Parent strain carrying pHCMC04
94.7 Overexpression of aroA
116.0 Overexpression of aroB
118.0 Overexpression of aroC
153.3 Overexpression of aroD
213.3 Overexpression of aroD plus aroA
199.3 Overexpression of aroD plus aroB
199.3 Overexpression of aroD plus aroC
194.0 Overexpression of aroD on two plasmids
207.3 Overexpression of tkt in BSSA/pSAAroA/pDGSAAroD
230.7 Knockout of pyk in BSSA/pSAAroA/pDGSAAroD
results from three parallel cultures and standard errors were provided for
Figure 2 Time courses of cell growth (a), glucose consumption (b), shikimic acid production (c), and 3-dehydroshikimic acid production (d)
of B. subtilis BSSA/pHCMC04/pDG148-stu (◊) and BSSA/pSAAroA/pDGSAAroD (▲) in M9 minimal medium supplemented with 5 g/L glucose.
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file 1: Table S1). The intracellular phenylalanine and
tyrosine were not labeled by 13C because the SA kinase
gene (aroI) was mutated in both strains and de nova
synthesis of these amino acids from glucose was blocked.
We measured the 13C label state of extracellular shikimate
by using LC-MS (Additional file 1: Table S1). To assess if
the isotopic steady state was achieved, samples were taken
at different time points during the exponential growth
phase. The determined mass isotopomer distributions of
key amino acids were almost unchanged with the time of
harvest, which showed that a (quasi-) steady state could
be reached during the exponential growth phase in batch
cultures. From the GC-MS and LC-MS data (AdditionalTable 2 Determination of growth (OD600), specific cell growth
shikimic acid production rate (qsa), and specific 3-dehydroshi
BSSA/pHCMC04/ pDG148-stu and BSSA/pSAAroA/pDGSAAroD
Strains μ (h−1) qglu (mmol
BSSA/pHCMC04/ pDG148-stu 0.434 ± 0.023 5.199 ±
BSSA/pSAAroA/pDGSAAroD 0.332 ± 0.015 4.666 ±
Data are from 3 parallel cultivations and standard deviations are provided. B. subtili
medium, which was supplemented to 5 g/L glucose. Temperature and the shakingfile 1: Table S1), the 13C labeling patterns of the precursor
metabolites were identified, which allowed us to determine
the metabolic flux ratios. The absolute net fluxes were
then quantified by combining the flux ratios, physiological
data (Table 1), and the biomass composition data [18].
The intracellular flux distribution in the parent strain
BSSA/pHCMC04/pDG148-stu and high SA-producing
strain BSSA/pSAAroA/pDGSAAroD are shown in Figure 3.
Overall metabolic fluxes and responses of shikimate pathway
We observed a significant flux redistribution of several
metabolic reactions in responses to the overexpression of
plasmid-encoded aro genes in the high SA-producing strain
BSSA/pSAAroA/pDGSAAroD. The overall conversion ofrate (μ), specific glucose consumption rate (qglu), specific
kimic acid production rate (qdhs) of B. subtilis strains
g−1 h−1) qsa (mmol g
−1 h−1) qdhs (mmol g
−1 h−1)
0.120 0.101 ± 0.011 0.132 ± 0.013
0.132 0.159 ± 0.014 0.048 ± 0.007
s strains were cultivaeted 250-mL flasks that contained 50 mL of M9 minimal
rate of the incubator were held constantly at 37°C and 200 rpm, respectively.
Figure 3 Metabolic flux distribution in B. subtilis BSSA/pHCMC04/pDG148-stu (a) and BSSA/pSAAroA/pDGSAAroD (b) during exponential
growth phase. The estimated net fluxes were percentages of the relative rates normalized to the glucose uptake rates. Directions of net fluxes were
represented by arrows. The gray arrows indicated flux related to biomass formation and fermentation products. The flux distributions were obtained from
the best fit to the quantitative physiological data and the constraints derived from the MS measurements. F6P, fructose-6-phosphate; GAP, Glyceraldehyde
3-phosphate; AcCoA, acetyl-CoA; ICT, isocitrate; AKG, a-ketoglutarate; S7P, sedoheptulose-7-phosphate; DHS, 3-dehydroshikimic acid; SA, shikimic acid.
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BSSA/pSAAroA/pDGSAAroD from 4.4% in strain BSSA/
pHCMC04/pDG148-stu. Consequently, the metabolic
flux to SA increased from 1.9% in strain BSSA/pHCM
C04/pDG148-stu to 4.6% in strain BSSA/pSAAroA/
pDGSAAroD. We observed that the production rate of
3-dehydroshikimic acid decreased to 0.048 mmol g−1 h−1 in
strain BSSA/pSAAroA/pDGSAAroD from 0.132 mmol
g−1 h−1 in the parent strain BSSA/pHCMC04/pDG148-stu
(Table 2). Correspondingly, the metabolic flux from E4P
and PEP into DHS decreased from 2.5% in the parent
strain BSSA/pSAAroA/pDGSAAroD to 2.2% in strain
BSSA/pSAAroA/pDGSAAroD. The reversible reaction
converting DHS to SA and being catalyzed by SA dehydro-
genase (AroD) increased its flux by 2.4 folds (from 1.9% in
BSSA/pHCMC04/pDG148-stu to 4.6% in BSSA/pSAAroA/
pDGSAAroD) in strain BSSA47407 (Figure 3).
Flux shifts of TCA cycle, EMP and PPP pathways
As shown in Figure 3, the flux through the TCA cycle was
81.6% relative to the glucose uptake rate in BSSA/
pHCMC04/pDG148-stu, while this flux decreased to
69.7% in BSSA/pSAAroA/pDGSAAroD. The overall flux
of TCA cycle reduced significantly in the high SA-
producing strain BSSA/pSAAroA/pDGSAAroD, sug-
gesting a weak TCA cycle during high production of SA
with B. subtilis. In contrast, fluxes of the EMP and pen-
tose phosphate pathways did not shift significantly,
except the reactions involving E4P generation andconsumption. In the PPP pathway, transketolase,
encoded by tkt, catalyzes reversible reaction (see Add-
itional file 1: Appendix S1) and is that to E4P flux. We did
not observe significant changes of flux driven by the
transaldolase (v6). However, the net flux of reaction
encoded by tkt decreased from 4.6% in the parent strain
BSSA/pHCMC04/pDG148-stu to 1.3% in the high SA-
producing strain BSSA/pSAAroA/pDGSAAroD, suggest-
ing that this reaction was severely disturbed and might be
interesting to see how the SA synthesis would be influ-
enced if tkt were overexpressed.
Supply of PEP for SA synthesis
PEP is one of the initial substrates for shikimate synthesis.
In almost all known microorganisms, the DAHP synthase
catalyzes the condensation of PEP and E4P, which is the
first reaction of the shikimate pathway. It is reasonable to
consider any changes of PEP generation and consumption
in the high SA-producing BSSA/pSAAroA/pDGSAAroD.
Two reactions were considered in this study for generation
of PEP: 1) The enolase (NP_391270.1, EC:4.2.1.11) catalyzes
glycerate-2-phosphate into PEP (v8, see Additional file
1: Appendix S1). 2) The PEP-forming ATP:oxaloacetate
carboxylyase (also named PEP carboxykinase, PckA, NP_39
0934.2, EC:4.1.1.49) catalyzes the conversion of oxaloacetate
into PEP (v10, see Additional file 1: Appendix S1). As shown
in Figure 3, flux into reaction v8 decreased from 160.3% in
BSSA/pHCMC04/pDG148-stu to 150.2% in BSSA/pSAAro
A/pDGSAAroD, and flux into reaction v10 reduced from
Liu et al. Microbial Cell Factories 2014, 13:40 Page 6 of 11
http://www.microbialcellfactories.com/content/13/1/4044.3% in BSSA/pHCMC04/pDG148-stu to 21.4% in BSSA/
pSAAroA/pDGSAAroD. Meanwhile, we also observed that
the conversion of PEP into pyruvate, which is encoded by
pyk, also decreased, from 194.2% in BSSA/pHCMC04/
pDG148-stu to 159.0% in BSSA/pSAAroA/pDGSAAroD.
Taking all these flux information, we considered that the
supply of PEP might in shortage in the high SA-producing
BSSA/pSAAroA/pDGSAAroD. In addition, we observed
that the flux of reaction (v9) in the SA-producing BSSA/
pSAAroA/pDGSAAroD was still high (159%). For the
purpose to increase supply of PEP to shikimate synthe-
sis, knockout of this pyk might be a choice to increase
SA production.
Validation of MFA results: effects of tkt overexpression
and pyk deletion on SA production
Based on the previous results, we selected two targets
for further genetic manipulation and to improve the SA
production in B. subtilis. For the purpose to increase
carbon flux to PEP, efforts were made to overexpress tkt
in BSSA/pSAAroA/pDGSAAroD. However, the resulting
strain BSSA/Ωtkt::pSAtkt did not show significant changes
in SA production (Table 1). Further efforts were make to
knock out the pyruvate kinase thus would diminish the flux
of PEP into pyruvate. The resulting strain BSSA/Ωpyk::
pSApyk produced 3.46 g/L of SA, an increase of 8% com-
pared to its parent strain BSSA/pSAAroA/pDGSAAroD.
Discussion
In this study, we investigated the influence of overexpres-
sion of aro genes on the accumulation of SA, and we con-
structed high SA producers by overexpression of aroA
and aroD in B. subtilis. Our results demonstrated that
overexpression of plasmid-encoded aroD increased the ac-
cumulation of SA, suggesting that AroD-driven reduction
of 3-dehydroshikimate into SA was rate-limiting step for
SA accumulation in B. subtilis. This is different from that
of E. coli, of which the condensation of PEP and E4P into
DAHP is the rate-limiting reaction and this reaction is
subjected to extensive feedback regulations [19-21].
13C-MFA revealed carbon flux redistributions into shi-
kimate pathway and TCA cycle, and reactions involving
generation and consumption of PEP and E4P in genetic-
ally modified B. subtilis for SA production. Based on the
MFA results in this study and previous investigation on
E. coli [7,8,13], tkt and pyk were selected to be targets
for genetically modification and for improvement of SA
production with B. subtilis. Previous investigations showed
that transformation with plasmid carrying tktA that
encodes transketolase I increased the availability of E4P,
and therefore increased SA and aromatic amino acid
productions in E. coli [13]. However, this study showed
that overexpression of tkt did not increased SA production
in B. subtilis, a remarkable difference from that in E. coli.Since transketolase catalyzes a reversible reaction (see
Additional file 1: Appendix S1), i.e., it generates E4P in
one direction but consumes E4P in the other direction, we
deduced that the tkt-encoded transketolase in B. subtilis
catalyzed reaction more favored to direction of fructose
6-phosphate and glyceraldehyde 3-phosphate, and that
the tktI-encoded transketolase in E. coli more favored the
formation of E4P and xylulose 5-phosphate. Confirmation
of this deduction needs further biochemical evidences on
catalytic properties of the transketolases from B. subtilis
and E. coli. These results suggest that MFA data need to
be carefully interpreted and conclusions from MFA need
to be experimentally confirmed, and application of MFA
data from one bacterial species may be different from that
of another bacterial species.
Based on MFA results as well as previous investigations
in E. coli [7], a second target was spotted for knockout
of pyk, so that consumption of PEP by this Pyk-driven
reaction would be vanished. Pyruvate kinase, encoded
by pyk, is an enzyme involved in glycolysis and catalyzes
the consumption of one molecule of PEP, yielding one
molecule of pyruvate and one molecule of ATP. Previous
investigation revealed that PEP increased its intracellular
pools when pyk was deleted [22]. We observed that SA
production increased by 8% in B. subtilis, from 3.2 g/L
in the control strain BSSA/pSAAroA/pDGSAAroD to
3.46 g/L in strain BSSA/Ωpyk::pSApyk. This result is again
different from that observed in E. coli pyk mutant, which
did not showed obvious increase of intracellular PEP level
[22]. Careful exploration of metabolic networks in B.
subtilis and E. coli suggested that they have very different
reactions at the PEP-pyruvate-oxaloacetate node, particu-
larly the reactions for PEP and oxaloacetate generation/
consumption [23]. As demonstrated in previous studies,
the pyk mutant of B. subtilis maintained high intracellular
PEP levels [22] and produced less acetic acid than wild
type did. This invoked the enthusiasm on exploitation of
B. subtilis pyk mutants for production of various aromatic
compounds. For example, B. subtilis strain BSTZ0402, an
inducible pyk mutant, had been successfully constructed
and yielded three folds higher folic acids compared to the
parent strain B. subtilis 168 [24]. Additional works on
mining the 13C-MFA data and exploitation of metabolic
network from B. subtilis for improving SA productivity
are in progress.
Conclusion
Based on the data obtained in this study, it was concluded
that overexpression of plasmid-encoded aroD exerted
most significant influence on SA accumulation in B.
subtilis. Co-everexpression of plasmid-encoded aroA
and aroD doubled SA production than its parent strain
BSSA/pHCMC04. So far as we know, this is the first
time to quantify the flux flow in SA producing B.
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among phosphate pentose pathway, glycolysis, TCA cycle
in the low and high SA-producing B. subtilis strains. The
high SA producing strain BSSA/pSAAroA/pDGSAAroD
had increased carbon flux into shikimate pathway and
reduced flux into TCA cycle. Based on the MFA results,
tkt and pyk were targeted for improving SA production by
B. subtilis. Overexpression of plasmid-encoded tkt did not
increase SA production, and the deletion of pyk increased
SA production by 8% in B. subtilis. The results showed
that B. subtilis and E. coli had very different responses to
genetic manipulations of the aro genes involving shikimate
pathway and the tkt and pyk involving PEP/E4P generation
and consumption.
Materials and methods
Microorganisms, plasmids, cultivation, and determination
of cell growth
The bacterial strains, plasmids, and primers used in this
study are listed in Table 3. B. subtilis strains 1A474 and
168 were obtained from the Bacillus Genetic Stock Center
(BGSC) at the Ohio State University (http://www.bgsc.
org/). Both B. subtilis and E. coli were routinely cultivated
in Luria Bertani (LB) broth at 37°C. When needed, antibi-
otics were included at the following concentrations,
15 μg/mL of erythromycin, chloramphenicol of 5 μg/mL,
ampicillin of 100 μg/mL and neomycin of 30 μg/mL.
Cell growth was monitored by optical density mea-
surements at 600 nm (OD600) using a UV/visible spec-
trophotometer. Cellular dry weights were determined with
duplicate samples of culture broth, by precipitation of cells
and washed with distilled water and lyophilization.
Determination of SA and 3-dehydroshikimic acid by high
performance liquid chromatography (HPLC)
B. subtilis was cultivated in LB broth at 37°C and at
200 rpm, overnight, and cells from culture were used as
inoculum. SA production was determined in triplicates
after 90 h cultivation at 37°C and 200 rpm in 250-mL
flasks that contained 50 mL of fermentation broth. The
fermentation broth was modified from Iomantas et al. [17]
by deletion of maltose, and had the following components
(g/L): K2HPO4 · 3H2O (18.3); KH2PO4 (6); Urea (6); sucrose
(80); MgSO4 · 7H2O (1); FeSO4 (0.01); MnSO4 (0.01); Yeast
Extract (4). For induction of the target gene overexpression
in recombinant B. subtilis strains, IPTG at final concentra-
tion of 0.05 mM and xylose at final concentration of 5 g/L
were added into the fermentation broth.
SA and 3-dehydroskimic acid accumulation in culture
supernatant was determined with an HPLC system (Agilent
1200 series) equipped with a SB C18 column (4.6 mm×
250 mm× 5 μm). Five ml samples of fermentation broth
were centrifuged at 13,000 rpm for 5 min on Microfuge® 18
centrifuge (BECKMAN COULTERTM) to remove cells, andthe supernatant was applied for HPLC analysis. The HPLC
was run with mixture of solution A (phosphoric acid in
water, pH 2.5) and solution B (methanol) as eluant and
was operated at a flow rate of 0.35 mL/min. SA and 3-
dehydroshikimic acid were detected at 215 nm with
adiode array detector. The following gradient was used: at
0–7.5 min, 95% of solution A and 5% of solution B; at 7.5-
8.0 min, 100% of solution B; at 8.0-15 min, 100% of solution
B; 15.0-15.5 min, 95% of solution A and 5% of solution B;
15.5-22.5 min, 95% of solution A and 5% of solution B.
Standard SA and 3-hydroskimic acid were eluted at 5.411
and 6.241 min, respectively, under these conditions.
Determination of glucose concentrations
Glucose concentrations were enzymatically determined
with glucose oxidase kit by using a bioanalyzer, according
to producer’s description (SBA-40C, Shandong Academy
of Sciences).
DNA extraction, amplification, plasmid construction and
genetic transformation
Plasmid and chromosomal DNAs were isolated using
the Plasmid Minspin HP Kit and the SiMax™ Genome
DNA Kit, respectively. Purification of DNA fragments from
agarose gels was done with the TIANgel Midi Purification
Kit. Restriction enzymes, ligases and other DNA-manipu-
lating enzymes were used according to their manufacturer’s
instructions.
The aro genes involving shikimate pathway, i.e., aroA
(Genbank accession number, NP_390853.1), aroB (NP_3
90151.1), aroC (NP_390189.1), and aroD (NP_390444.2)
were PCR amplified from genomic DNA of B. subtilis
strain 168 using primers listed in Table 3. The PCR
products were digested with SpeI and XmaI and then
cloned into the same digested pHCMC04 [25]. All plasmids
(Table 3) constructed in this study were verified by DNA
sequencing. Transformation of chemically competent cells
of E. coli DH5 and of B. subtilis were carried out according
to the manufacturer’s manual or by the method of Spizizen
[26]. In order to simultaneous overexpression of aroA
and aroD in B. subtilis, aroD was cloned into the
pDG148-Stu vector [27], and the resulted plasmid was
named pDGSAAroD (Table 3). Expression of the cloned
aro genes in B. subtilis was induced by either 5 g/L of
xylose for pHCMC04 derivatives or 0.05 mM IPTG for
pDG148-Stu derivative.
Cloning and overexpression of tkt (NP_389672.10) in
B. subtilis were performed with the plasmid pMUTIN4
[28]. The tkt with its ribosome binding site (RBS) was
amplified by using primers listed in Table 3 and was cloned
into the BamHI-XmaI treated backbone of pMUTIN4.
Transformation of E. coli DH5α and B. subtilis BSSA/
pSAAroA/pDGSAAroD and selection of transformants
were performed as previously described. The B. subtilis
Table 3 Bacillus subtilis strains, plasmids, and primers used in this study
Strains/plasmids/primers Relevant characteristics Source/notes
Strains
168 trpC2 BGSC
1A474 amyE3 aroI10 BGSC
BSSA/pHCMC04 1A474 carrying pHCMC04 This work
BSSA/pSAAroA 1A474 carrying pSAAroA This work
BSSA/pSAAroB 1A474 carrying pSAAroB This work
BSSA/pSAAroC 1A474 carrying pSAAroC This work
BSSA/pSAAroD 1A474 carrying pSAAroD This work
BSSA/pHCMC04/ pDG148-stu 1A474 carrying pHCMC04 and pDG148-stu This work
BSSA/pHCMC04/ pDGSAAroD 1A474 carrying pHCMC04 and pDGSAAroD This work
BSSA/pSAAroA/ pDGSAAroD 1A474 carrying pSAAroA and pDGSAAroD This work
BSSA/pSAAroB pDGSAAroD 1A474 carrying pSAAroB and pDGSAAroD This work
BSSA/pSAAroC pDGSAAroD 1A474 carrying pSAAroC and pDGSAAroD This work
BSSA/pSAAroD pDGSAAroD 1A474 carrying pSAAroD and pDGSAAroD This work
BSSA(Ωtkt::pSATkt) BSSA/pSAAroA/pDGSAAroD harboring Ωtkt::pSATKT This work
BSSA(Ωpyk::pSAPyk) BSSA/pSAAroA/pDGSAAroD harboring Ωpyk::pSAPYK This work
Plasmids
pHCMC04 bla PxylA xylR cat BGSC
pDG148-stu neo ble Pspac lacI bla BGSC
pMUTIN4 bla Pspac lacZ lacI ermC BGSC
pSAAroA pHCMC04 derivative, aroA expressed from PxylA This work
pSAAroB pHCMC04 derivative, aroB expressed from PxylA This work
pSAAroC pHCMC04 derivative, aroC expressed from PxylA This work
pSAAroD pHCMC04 derivative, aroD expressed from PxylA This work
pDGSAroD pDG148-stu derivative, aroD expressed from Pspac This work
pSATkt bla Pspac-tkt-lacZ lacI ermC This work
pSAPyk bla Pspac-pyk’-lacZ lacI ermC This work
Primers
aroA-fw-SpeI TCAACTAGTATGAGCAACACAGAGTTAG Cloning of aroA into pHCMC04
aroA-rv-XmaI TCACCCGGGTTAAGCGTTGACTTTCAC
aroB-fw-SpeI TCCACTAGTATGAAGACACTGCATGTTC Cloning of aroB into pHCMC04
aroB-rv-XmaI TCAGGATCCTCATGATGTCTCCTCCAATC
aroC-fw-SpeI TCAACTAGTGTGAACGTGTTAACGATTAAAG Cloning of aroC into pHCMC04
aroC-rv-XmaI TCACCCGGGCTATCCCCGTGTGTTTTTATG
aroD-fw-SpeI TCCACTAGTATGAAAAAGCTGTACGG Cloningof aroD into pHCMC04
aroD-rv-XmaI TCAGGATCCTTAACATTCTGTTCCTCC
aroD-DG-fw AAGGAGGAAGCAGGTATGAAAAAGCTGTACGG Cloning of aroD into pDG148-stu
aroD-DG-rv GACACGCACGAGGTTTAACATTCTGTTCCTCC
tkt-Mu-fw-XmaI ACTCCCGGGACATAAGGAAGGGGATTTTTATG Cloning of tkt into pMUTIN4
tkt-Mu-rv-BamHI ACTGGATCCACTCATCCTCTTTCAAAAGC
tkt-ck-fw TTTCAGGAATACATAGAG Confirming the integration of pSATKT
tkt-ck-rv TTAGACAAAATTTCTTTC
pyk-Mu-fw-XmaI CCCCCGGGGAAGATTTCAGAAGGAAGTGAACC Cloning 5’ end of pyk into pMUTIN4
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Table 3 Bacillus subtilis strains, plasmids, and primers used in this study (Continued)
pyk-Mu-rv-BamHI CCGGATCCGGAATTTCCACACCTAAGTCTCC
pyk-ck-fw AACGTACATATGTAATCG Confirming the integration of pSAPYK
pyk-ck-rv CCGTTCAGCAAAAATAAAAC
BGSC: Bacillus Genetic Stock Center. Resistance gene abbreviations as follows: bla, ampicillin; ermC, erythromycin and lincomycin; cat, chloramphenicol; neo,
kanamycin. Other abbreviation: Ω, insertion of integrated plasmid. Restriction sites were underlined.
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15 ug/mL erythromycin, 5 ug/mL chloramphenicol, 30
ug/mL neomycin and then analyzed by PCR to ensure
the integration of a single copy of the plasmid into the
target gene on the chromosome.
Construction of an inducible pyk mutant
The plasmid pMUTIN4 was also used to produce knock-
out mutations [28]. The fragment of 5’ end of pyk (NP_3
90796.1) with its RBS was amplified from Bacillus subtilis
168 chromosomal DNA using primers listed in Table 3,
and was cloned into the BamHI-XmaI treated backbone
of pMUTIN4. Transformation of E. coli DH5α and B.
subtilis BSSA/pSAAroA/pDGSAAroD were performed as
previously described. The B. subtilis transformants were
selected on LB plates containing 15 μg/mL erythromycin,
5 μg/mL chloramphenicol, 30 μg/mL neomycin and
1 mM IPTG and then analyzed by PCR to ensure that
the pyk gene had been knocked out.
Growth and cultivation of B. subtilis with
13C-labeled glucose
The chemically defined M9 minimal medium [29] was
applied for the 13C labeling experiment. Glucose was added
to M9 minimal medium as either entirely the [1-13C]-
labeled isotope isomer (99%; Cambridge Isotope Labora-
tories Inc., Andover, MA) or as a mixture of 20% (w/w)
[U-13C] (99%; Cambridge Isotope Laboratories Inc.)
and 80% (w/w) unlabeled glucose. B. subtilis strains
pre-cultivated overnight in 5 mL of M9 minimal medium
supplemented with 5 g/L unlabeled glucose, and the pre-
cultures (2 mL) were used as inoculum for 13C-labeling
experiments. The 13C-labeling experiments were performed
in a 250-mL flask that contained 50 mL of M9 minimal
medium, which was supplemented with either 20:80 (w/w)
mixture of [U-13C] glucose:unlabeled glucose or 100%
[1-13C] glucose. Temperature and the shaking rate of the
incubator were held constant at 37°C and 200 rpm, re-
spectively. When cells reached exponential phase, aliquots
of 0.5 mL was aseptically collected from the culture at
intervals of 0.5 h. Measure the OD600 on a spectrometer
to monitor the growth of the cells. For extracellular me-
tabolite (shikimic acid and 3-dehydroshikimic acid) ana-
lysis by HPLC, culture samples were centrifuged for 5 min
at 4°C and 20,000 g to remove the cells. The specific
growth rate (μ) was defined as the increase in cell biomassconcentration per unit time. The specific glucose con-
sumption rate (qglu) was calculated during the exponential
growth phase as the differential change in glucose with
time (t) normalized to the biomass concentration. The
specific SA production rate (qsa), and the specific 3-dehy-
droshikicmic acid production rate (qdhs) were calculated
during the exponential growth phase as the differential
change in SA, and 3-dehydroshikicmic acid with time (t)
normalized to the biomass concentration, respectively.
Preparation of cellular hydrolysate from 13C-labeled
biomass and measurements of 13C-labeled amino acids
with gas chromatography and mass spectroscopy (GC-MS)
Preparation of cellular hydrolysate from 13C-labeled bio-
mass for the GC-MS measurement followed standard
protocols [30]. For GC-MS measurement, the amino acids
were derivatized with TBDMS and 1% tert-butyldimethyl-
chlorosilane at 85°C for 60 min. The amounts of biomass
used for GC-MS measurement was approximately 10 mg
of cellular dry weight. GC-MS was carried out using an
Agilent GC-7890A gas chromatograph equipped with an
Agilent HP-5MS column (30 m× 0.25 mm× 0.25 mm) that
was directly connected to an MS-5975C mass spectrometer
(Agilent). The following amino acids were detected: Ala,
Asp, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Tyr, and Val.
Determination of 13C-labeled SA and 3-dehydroshikimic
acid with LC-MS
Agilent 1290 UHPLC system equipped with ZORBAX
300SB-C18 Column (2.1 mm × 100 mm × 1.8 μm) and
Agilent 6530 Q-TOF mass spectrometer fitted with an
electrospray ionization (ESI) source were used to measure
13C-labeling states of SA and 3-dehydroshikimic acid. SA
and 3-dehydroshikimic acid was eluted with mixture of
0.1% formic acid in water (solution C) and acetonitrile
(solution D) at ratio of 98:2 (solution C: solution D) and at
a flow rate of 0.15 mL/min. MS data was collected in
negative ion mode. The capillary voltage was set to
3500 kV, and the fragmentor voltage at 90 V. The drying
gas temperature was maintained at 350°C with a flow rate
of 11 L/min and a nebulizer pressure of 40 psi.
Metabolic net-flux analysis
13C MFA was a well-established method, and details
concerning the general modeling framework of classical
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elsewhere [30]. In the case of U-13C labeling, several flux
ratios, including (1) Pyr originating from malate, (2) PEP
from OAA, (3) OAA from PEP, (4) PEP from trans-
ketolase, (5) PEP from the PP pathway, (6) pentose-5-
phosphate from Glu-6-P, (7) OAA from the glyoxylate
shunt, (8) erythrose-4-phosphate from pentose-5-phosphate,
(9) Ser from Gly, (10) Gly from Ser, and (11) PEP and E4P
from shikimic acid were calculated from the MDVM of
precursors (Additional file 1: Table S2) with probabilistic
equations. The calculating procedures were based on the
general principle of flux ratio analysis [30-32] and were
performed using a home-made Matlab program. Positional
labeling pattern was also analyzed from cells grown exclu-
sively on [1-13C] glucose to obtain precise information
about the in vivo activities of the PPP and EMP pathways.
For quantification of carbon fluxes in B. subtilis, a
bioreaction network was constructed. This network
includes the reactions of the EMP, PP, and shikimate
pathways, as well as the tricarboxylic acid (TCA) cycle
and the glyoxylate shunt. The reactions catalyzed by
PEP carboxykinase (v10), pyruvate carboxylase (v11), and
malic enzyme (v12) were also included. The networks of
active pathways identified by flux ratio analysis were used
for flux quantification. The following enzyme reactions
were considered reversible: phosphoglucose isomerase
(v2), transketolase (v5 and v7), transaldolase (v6), the
sequence of glycolytic reactions leading from triose
3-phosphate to PEP (v8) and malate dehydrogenase
(v17). The metabolic reactions considered as shown in
the Additional file 1: Appendix S1.
All the above data, including (1) the stoichiometric reac-
tion matrix, (2) the flux ratios derived from metabolic flux
ratio analysis (Additional file 1: Table S3), (3) physiological
data, and (4) precursor requirements for biomass synthe-
sis, were utilized to calculate absolute fluxes in millimoles
per gram of biomass per hour. Net fluxes were then
estimated with Matlab by solving the stoichiometric
matrix. The resulting flux distribution was the best fit
to available data from both metabolite balances and
tracer experiment-based flux ratios within the specified
metabolic model.
Statistical analysis
Monte Carlo approach [33] was applied for statistical
analysis.
Additional file
Additional file 1: Table S1. Mass isotopomer distribution of TBDMS-
derivatized protein-bound amino acids and shikimic acid (corrected). Table
S2. Mass isotopomer distribution of precursors. Table S3. Flux ratio of Bacillus
subtilis BSSA/pHCMC04/pDG148-stu and Bacillus subtilis BSSA/pSAAroA/
pDGSAAroD. Figure S1. 13C fractional labeling (FL) of 15 proteinogenic aminoacids and shikimic acid from Bacillus subtilis BSSA/pHCMC04/pDG148-stu (a)
and Bacillus subtilis BSSA BSSA/pSAAroA/pDGSAAroD (b) during exponential
growth phase. Appendix S1. Stoichiometric reactions implemented in
the central metabolic network of Bacillus subtilis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SJL and CY conceived and designed the experiments. DFL and GMA
performed the experiments. DFL, YML, QXZ, LXL, BZ, CL, CYJ, CY and SJL
analyzed the data. DFL and SJL wrote the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by 973 Project from Ministry of Science and
Technology (No. 2012CB7211-04).
Author details
1State Key Laboratory of Microbial Resources, Institute of Microbiology,
Chinese Academy of Sciences, Beijing 100101, China. 2School of Life
Sciences, University of Science and Technology of China, Hefei 230026,
China. 3Key Laboratory of Synthetic Biology, Institute of Plant Physiology and
Ecology, Shanghai Institute for Biological Sciences, Chinese Academy of
Sciences, Shanghai 200032, China. 4Institute of Microbiology, Chinese
Academy of Sciences, Beichen-Xilu, Beijing, Chaoyang District 100101, China.
Received: 30 November 2013 Accepted: 21 February 2014
Published: 14 March 2014
Reference
1. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler
EN, Wallis TR, Klimov AI, Gubareva LV: Surveillance for neuraminidase in-
hibitor resistance among human influenza A and B viruses circulating
worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008,
52:3284–3292.
2. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC,
Marshall SA, George KS, Epperson S, Brammer L, Klimov AI, Bresee JS, Fry
AM: Infections with oseltamivir-resistant influenza A(H1N1) virus in the
United States. Jama-j Am Med Assoc 2009, 301:1034–1041.
3. Bradley D: Star role for bacteria in controlling flu pandemic? Nat Rev Drug
Discov 2005, 4:945–946.
4. Enrich LB, Scheuermann ML, Mohadjer A, Matthias KR, Eller CF, Newman MS,
Fujinaka M, Poon T: Liquidambar styraciflua: a renewable source of
shikimic acid. Tetrahedron Lett 2008, 49:2503–2505.
5. Lingens F: Biosynthesis of aromatic amino acids and its regulation.
Angewandte Chemie-International Edition 1968, 7:350.
6. Kramer M, Bongaerts J, Bovenberg R, Kremer S, Muller U, Orf S, Wubbolts M,
Raeven L: Metabolic engineering for microbial production of shikimic
acid. Metab Eng 2003, 5:277–283.
7. Escalante A, Calderon R, Valdivia A, de Anda R, Hernandez G, Ramirez OT,
Gosset G, Bolivar F: Metabolic engineering for the production of shikimic
acid in an evolved Escherichia coli strain lacking the phosphoenolpyruvate:
carbohydrate phosphotransferase system. Microb Cell Fact 2010, 9:21.
8. Dell KA, Frost JW: Identification and removal of impediments to biocatalytic
synthesis of aromatics from D-glucose - rate-limiting enzymes in the
common pathway of aromatic amino-acid biosynthesis. J Am Chem Soc
1993, 115:11581–11589.
9. Knop DR, Draths KM, Chandran SS, Barker JL, von Daeniken R, Weber W,
Frost JW: Hydroaromatic equilibration during biosynthesis of shikimic
acid. J Am Chem Soc 2001, 123:10173–10182.
10. Chandran SS, Yi J, Draths KM, von Daeniken R, Weber W, Frost JW:
Phosphoenolpyruvate availability and the biosynthesis of shikimic acid.
Biotechnol Prog 2003, 19:808–814.
11. Yi J, Draths KM, Li K, Frost JW: Altered glucose transport and shikimate
pathway product yields in E-coli. Biotechnol Prog 2003, 19:1450–1459.
12. Patnaik R, Liao JC: Engineering of Escherichia-Coli central metabolism for
aromatic metabolite production with near theoretical yield. Appl Environ
Microb 1994, 60:3903–3908.
Liu et al. Microbial Cell Factories 2014, 13:40 Page 11 of 11
http://www.microbialcellfactories.com/content/13/1/4013. Patnaik R, Spitzer RG, Liao JC: Pathway engineering for production of
aromatics in Escherichia-Coli - confirmation of stoichiometric analysis by
independent modulation of Arog, Tkta, and Pps activities. Biotechnol
Bioeng 1995, 46:361–370.
14. Lu JL, Liao JC: Metabolic engineering and control analysis for production
of aromatics: role of transaldolase. Biotechnol Bioeng 1997, 53:132–138.
15. Draths KM, Knop DR, Frost JW: Shikimic acid and quinic acid: replacing
isolation from plant sources with recombinant microbial biocatalysis.
J Am Chem Soc 1999, 121:1603–1604.
16. Rodriguez A, Martinez JA, Baez-Viveros JL, Flores N, Hernandez-Chavez G,
Ramirez OT, Gosset G, Bolivar F: Constitutive expression of selected genes
from the pentose phosphate and aromatic pathways increases the
shikimic acid yield in high-glucose batch cultures of an Escherichia coli
strain lacking PTS and pykF. Microb Cell Fact 2013, 12:86.
17. Iomantas YAV, Abalakina EG, Polanuer BM, Yampolskaya TA, Bachina TA,
Kozlov YI: Method for producing shikimic acid. US patent 6436664 B1; 2002.
18. Sauer U, Hatzimanikatis V, Hohmann HP, Manneberg M, van Loon APGM,
Bailey JE: Physiology and metabolic fluxes of wild-type and riboflavin-
producing Bacillus subtilis. Appl Environ Microb 1996, 62:3687–3696.
19. Davies WD, Davidson BE: The nucleotide sequence of aroG, the gene for
3-deoxy-D-arabinoheptulosonate-7-phosphate synthetase (phe) in
Escherichia coli K12. Nucleic Acids Res 1982, 10:4045–4058.
20. Zurawski G, Gunsalus RP, Brown KD, Yanofsky C: Structure and regulation
of aroH, the structural gene for the tryptophan-repressible 3-deoxy-D-
arabino-heptulosonic acid-7-phosphate synthetase of Escherichia coli.
J Mol Biol 1981, 145:47–73.
21. Umbarger HE: Amino-acid biosynthesis and its regulation. Annu Rev
Biochem 1978, 47:533–606.
22. Fry B, Zhu T, Domach MM, Koepsel RR, Phalakornkule C, Ataai MM:
Characterization of growth and acid formation in a Bacillus subtilis
pyruvate kinase mutant. Appl Environ Microb 2000, 66:4045–4049.
23. Sauer U, Eikmanns BJ: The PEP-pyruvate-oxaloacetate node as the switch
point for carbon flux distribution in bacteria. FEMS Microbiol Rev 2005,
29:765–794.
24. Zhu T, Pan Z, Domagalski N, Koepsel R, Ataai MM, Domach MM:
Engineering of Bacillus subtilis for enhanced total synthesis of folic acid.
Appl Environ Microb 2005, 71:7122–7129.
25. Nguyen HD, Nguyen QA, Ferreira RC, Ferreira LCS, Tran LT, Schumann W:
Construction of plasmid-based expression vectors for Bacillus subtilis
exhibiting full structural stability. Plasmid 2005, 54:241–248.
26. Anagnostopoulos C, Spizizen J: Requirements for Transformation in
Bacillus subtilis. J Bacteriol 1961, 81:741–746.
27. Joseph P, Fantino JR, Herbaud ML, Denizot F: Rapid orientated cloning in a
shuttle vector allowing modulated gene expression in Bacillus subtilis.
FEMS Microbiol Lett 2001, 205:91–97.
28. Vagner V, Dervyn E, Ehrlich SD: A vector for systematic gene inactivation
in Bacillus subtilis. Microbiology-Uk 1998, 144:3097–3104.
29. Fuhrer T, Fischer E, Sauer U: Experimental identification and quantification
of glucose metabolism in seven bacterial species. J Bacteriol 2005,
187:1581–1590.
30. Nanchen A, Fuhrer T, Sauer U: Determination of metabolic flux ratios from
13C-experiments and gas chromatography–mass spectrometry data:
protocol and principles. Methods Mol Biol 2007, 358:177–197.
31. Fischer E, Sauer U: Metabolic flux profiling of Escherichia coli mutants in
central carbon metabolism using GC-MS. Eur J Biochem 2003, 270:880–891.
32. Yang C, Hua Q, Baba T, Mori H, Shimizu K: Analysis of Escherichia coli
anaplerotic metabolism and its regulation mechanisms from the
metabolic responses to altered dilution rates and phosphoenolpyruvate
carboxykinase knockout. Biotechnol Bioeng 2003, 84:129–144.
33. Mollney M, Wiechert W, Kownatzki D, de Graaf AA: Bidirectional reaction
steps in metabolic networks: IV. Optimal design of isotopomer labeling
experiments. Biotechnol Bioeng 1999, 66:86–103.
doi:10.1186/1475-2859-13-40
Cite this article as: Liu et al.: Metabolic flux responses to genetic
modification for shikimic acid production by Bacillus subtilis strains.
Microbial Cell Factories 2014 13:40.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
